Informed Prostate Cancer Patient Support

Iron nanorobots show their true mettle | KAUST Discovery : Multifunctional iron nanowires selectively obliterate cancer cells with a triple-punch combination attack.

View of Antagonizing GnRH receptors: A temporary ADT salvage maneuver for prostate cancer patients experiencing PSA failure with GnRH agonist

View of Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Phase III ARAMIS Trial Showed Significant Improvement in OS for Patients with Prostate Cancer | Cancer Network : The investigation of darolutamide plus ADT in men with non-metastatic castration-resistant prostate cancer indicated a significant improvement in overall survival in this patient population.

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients - Full Text View - ClinicalTrials.gov : Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients - Full Text View.

Bayer's Nubequa Posts Significant OS Data as it Fights for Market Share in Prostate Cancer | BioSpace : The new data should give Bayer’s Nubequa some energy to go after market share held by other drugs approved to treat prostate cancer, including Pfizer’s Xtandi.

Immune Profiling After HDR in Local Relapsed Prostate Cancer - Full Text View - ClinicalTrials.gov : Immune Profiling After HDR in Local Relapsed Prostate Cancer - Full Text View.

Bayer, Orion's Nubeqa significantly improves overall survival in Phase III prostate cancer study - FirstWord Pharma : FirstWord Pharma - Gain Access to the Information You Need Track the Companies, Products, and Regulatory Areas of Most Interest to You

Darolutamide Improves Survival in Nonmetastatic CRPC : Darolutamide plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer, according to results from a preplanned final OS analysis of the phase III ARAMIS trial.

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study : The objective was to investigate the proportion of men with metastatic prostate cancer in groups defined by T stage, Gleason Grade Group (GGG) and serum levels of prostate-specific antigen (PSA) and if PSA can be used to rule in metastatic prostate cancer when combined with T stage and GGG. We identified 102,076 men in Prostate Cancer data Base Sweden 4.0 who were diagnosed with prostate cancer in 2006–2016. Risk of metastases was assessed for PSA stratified on T stage and five-tiered GGG. For men who had not undergone bone imaging, we used multiple imputation to classify metastatic prostate cancer. Advanced T stage, high GGG and high PSA were related to bone metastases. For example: only 79/38 190 (0.2%) of men with T1-2 and GGG 1 had PSA above 500 ng/mL, and 29/79 (44%) of these men had metastases; whereas 1 154/7 018 (16%)

Discovery of New T-cell Raises Prospect of ‘Universal’ Cancer Therapy | Cooking with Kathy Man : Researchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy. T-cell therapies for cancer – where immune cells are re…

Radiopharmaceuticals Show Signs of Progress in Prostate Cancer : A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.

Bluestar Genomics’ Breakthrough Study Highlights Promising Data for Multi-Cancer Detection From a Single Blood Draw | Business Wire : Bluestar Genomics, a company developing innovative, data-driven, epigenomic approaches to comprehensive disease analysis and diagnostics, today announ

Study examines prostate cancer treatment decisions -- ScienceDaily : A five-year follow-up study of more than 2,000 US men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.

Prostate overtakes breast as 'most common cancer' - BBC News : Experts say more men are getting tested, which explains the rise in diagnoses in England.

Protein that hinders advancement of prostate cancer identified -- ScienceDaily : Researchers at Boston University School of Medicine (BUSM) have discovered that blocking a specific protein, may be a promising strategy to prevent the spread of castration-resistant prostate cancer (CRPC).

Treatment Stratification of Patients with Metastatic Castration-Resistant Prostate Cancer by Machine Learning: iScience : Bioinformatics; Cancer; Algorithms; Artificial Intelligence

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches - ScienceDirect : Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies a…

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer - Markowski - - The Prostate - Wiley Online Library : Background Immune checkpoint inhibition has been shown to have limited efficacy in patients with metastatic prostate cancer. Prostate cancers that harbor certain homologous recombination (HR) DNA re...

Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer | Cancer Discovery : In patients with metastatic castration-resistant prostate cancer, pembrolizumab showed efficacy.

Prostate cancer: only one in four men with metastatic disease gets recommended chemotherapy | The BMJ : A national audit shows that only one in four men with advanced prostate cancer receives life prolonging chemotherapy despite its recommendation by the National Institute for Health and Care Excellence (NICE). The National Prostate Cancer Audit’s annual report 2019 for England and Wales,1 published by the Royal College of Surgeons, reported for the first time on the use of primary docetaxel in metastatic disease. It found that only 27% of men with widespread disease received docetaxel, ranging from 0% to 39% by NHS providers in England. Noel Clarke, consultant urological surgeon, and Heather Payne, consultant clinical oncologist, who were joint clinical leads for the audit, said that the …

Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? - Andrews - - The Prostate - Wiley Online Library : Background Optimal sequencing of systemic therapy in the management for metastatic castration resistant prostate cancer (mCRPC) remains poorly elucidated. The CHAARTED and STAMPEDE studies have prov...

Tailored Pelvic PT May Curb Post-Prostatectomy Stress Incontinence, Pain : After prostate surgery, individualized pelvic physical therapy to relax or strengthen the pelvic muscles may be more effective for reducing stress urinary incontinence (SUI) and pelvic pain than muscle strengthening alone, researchers suggest.

Eating More Veggies Did Not Slow Prostate Cancer Progression : Clinical guidelines for prostate cancer survivors should not rely on epidemiologic data to support claims that a vegetable-rich diet could slow disease progression, caution US researchers.

Prostate Cancer: Adverse Effects Favor Less Invasive Tx Over Surgery | Medpage Today : May guide treatment selection, since disease-specific survival is nearly 100% for each approach

Harms From Prostate Cancer Tx Persist at 5 Years : Changes in urinary, bowel, and sexual function following treatment of prostate cancer diminish over time, but some persist 5 years later.

FREE Genetic Testing and Counseling for Men with Prostate Cancer — Cancer ABCs : Given the importance of knowing about your germline genetics, Cancer ABCs wants you to know that if you have prostate cancer there is currently a genetic company, Invitae that is offering you an opportunity to have your germline genetics tested for  free .  They will also

Immune discovery 'may treat all cancer' - BBC News : Research is at an early stage but scientists said it had huge potential for destroying cancers.

Review Article | Journal of Urology auajournals.org Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative MRI: A Systematic Review and Meta-Analysis J Olivier 2 minutes Abstract Objective: To systematically review the literature on predictive factors for csPCa diagnosis after nMRI in PCa-naïve patients. Evidence Acquisition: The Medline and Scopus databases were searched up to March 2019. The review protocol was published in the PROSPERO database (CRD42019125549). The clinical factors and markers studied were age, PSA, PSA isoforms, PSA density (PSAD), PCA3, prostate volume, family history, ethnicity, and risk calculators. The primary objective was to determine their predictive ability for csPCa diagnosis. Secondary objectives included meta-analysis of the NPV of nMRI when combined with these pred

Adult Urology | Journal of Urology auajournals.org Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study Hashim U. Ahmed 3 minutes Abstract Purpose: COMPARE (COMparing treatment options for ProstAte cancer) aimed to evaluate and quantify the trade-offs patients make between different aspects of active surveillance and definitive therapy. Methods: A Discrete Choice Experiment (DCE) tool was used to elicit patients’ preferences for different treatment characteristics in 34 urology departments. Patients with localised prostate cancer completed the DCE within one week of being diagnosed and before they made treatment decisions. The DCE was pre-tested (N=5) and piloted (n=106) with patients. Patients chose their preferred treatment profile based on six characteri

A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy - Li - - The Prostate - Wiley Online Library : Background The qualitative transcriptional characteristics, the within‐sample relative expression orderings (REOs) of genes, are highly robust against batch effects and sample quality variations. He...

Genetic Risk Score Associated with Patient Age at Prostate Cancer Diagnosis | Cancer Network : This research found that combining family history and a genetic risk score could better stratify inherited risk for developing prostate cancer.

New Computer Program Can Help Uncover Hidden Genomic Alterations that Drive Cancers : Cancer is rarely the result of a single mutation in a single gene. Rather, tumors arise from the complex interplay between any number of mutually exclusive abnormal changes in the genome, the combinations of which can be unique to each individual patient. To better characterize the functional context of genomic variations in cancer, researchers at University of California San Diego School of Medicine and the Broad Institute developed a new computer algorithm they call REVEALER.

Bryce Olson Wants To Raise Awareness About Precision Medicine. His Rallying Cry: 'Sequence Me' : Diagnosed with an aggressive form of prostate cancer, Bryce Olson thought he had less than two years to live. Thanks to precision medicine, he's still alive.

EPISODE 01 | BRYCE OLSON - Epic Sciences : In this first episode of Innovations in Cancer, we spoke with Bryce Olson, who was diagnosed with advanced prostate cancer at 44 years old. His google searches showed a grim prognosis of one year. Five years later, Bryce is active and continuing his passion for surfing.

Why Advanced Cancer Patients Need Genetic Sequencing | Freethink : Genomic sequencing saved his life. Now he wants everyone to have access.

'Sequence me': How genomic sequencing saved one patient's life | Healthcare IT News : Bryce Olson, healthcare strategist at Intel, shares how he kicked cancer thanks to precision medicine and his work to empower cancer patients.

Artificial intelligence in multiparametric prostate cancer imaging with focus on deep-learning methods - ScienceDirect : Prostate cancer represents today the most typical example of a pathology whose diagnosis requires multiparametric imaging, a strategy where multiple i…

ngs-patient-care-oncology-practice-brochure-web.pdf

Remarkable New T-Cell Discovery Can Kill Several Cancer Types in The Lab : The discovery of a new kind of immune cell receptor could pave the way for a new type of T-cell cancer therapy that can attack a diverse range of cancers in human patients without requiring tailored treatment.

How to manage the side effects of prostate cancer treatment : There are currently more than three million men living with prostate cancer in the U.S.  Many of them are also living with side effects caused by their treatment.

Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries | SpringerLink : Purpose Thanks to the introduction of more sensitive/specific imaging and minimally invasive treatment techniques, the oligometastatic state in prostate cancer (PCa) has attracted the interest of the...

Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance | Nowroozi | Urology Journal : Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer | Nature Communications : Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression a

Translational Bioinformatics for Diagnostic and Prognostic Prediction of Prostate Cancer in the Next-Generation Sequencing Era : The discovery of prostate cancer biomarkers has been boosted by the advent of next-generation sequencing (NGS) technologies. Nevertheless, many challenges still exist in exploiting the flood of sequence data and translating them into routine diagnostics ...

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer - S0092-8674(18)30842-0.pdf

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet : Compliance with the FDAAA 2007 is poor, and not improving. To our knowledge, this is the first study to fully assess compliance with the Final Rule of the FDAAA 2007. Poor compliance is likely to reflect lack of enforcement by regulators. Effective enforcement and action from sponsors is needed; until then, open public audit of compliance for each individual sponsor may help. We will maintain updated compliance data for each individual sponsor and trial at fdaaa.trialstracker.net.

Urinary retention: Causes, treatment, and symptoms : Urinary retention can cause the need to urinate very frequently, the urge to urinate again straight after using the bathroom, or incontinence. Read more here.

The development and validation of prostate cancer-specific physician-hospital networks - Urology : To develop prostate cancer-specific physician-hospital networks to define hospital-based units that more accurately group hospitals, providers, and the patients they serve.

The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation | The British Journal of Radiology | Ahead of Print

Artificial Intelligence Might Help Spot, Evaluate Prostate Cancer | Cooking with Kathy Man : Amy Norton wrote . . . . . . . . . In another step toward using artificial intelligence in medicine, a new study shows that computers can be trained to match human experts in judging the severity o…

Prostate Cancer: Adverse Effects Favor Less Invasive Tx Over Surgery | Medpage Today : May guide treatment selection, since disease-specific survival is nearly 100% for each approach

Towards multi-drug adaptive therapy | Cancer Research : A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment sensitive cells to survive. These, in turn, suppress proliferation of the less fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multi-drug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology : PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspec

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | Cancer Biomarkers | JAMA Network Open | JAMA Network : This secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial estimates the long-term risk of any prostate cancer and clinically significant prostate cancer associated with baseline prostate-specific antigen (PSA) levels among men aged 55 to 60 years.

Prostatectomy Linked to More Incontinence, Sexual Dysfunction at 5 Years : NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary

Prostate cancer deaths in UK hit record high of over 12,000 in 2017 | Society | The Guardian : Disease is most common cancer in men in UK but rise is largely due to ageing population

FDA Grants Priority Review to Rucaparib for BRCA1/2-Positice mCRPC | Cancer Network : The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

To the Horizon: The Brink of an AI Revolution in Prostate Cancer? - The American Journal of Medicine : Noorbakhsh-Sabet et al.1 published an excellent review in The American Journal of Medicine summarizing the potential of artificial intelligence (AI) in medicine. They describe wide utility (e.g. in dermatology and stroke), but do not consider surgery and urology, which embrace cutting-edge technology, including fusion-biopsy and robotics,2 and will be early AI adopters. Indeed, prostate cancer creates a huge health care burden, thus being ideal for AI transformation.

Comprehensive Lifestyle Improvement Program for Me With Prostate Cancer 2 (CLIPP2) - Full Text View - ClinicalTrials.gov : Comprehensive Lifestyle Improvement Program for Me With Prostate Cancer 2 (CLIPP2) - Full Text View.

UC San Diego Health Sciences: From the Newsroom — Men Over 70 May Benefit from Prostate Cancer... : Men Over 70 May Benefit from Prostate Cancer Screening One in 9 men will be diagnosed with prostate cancer in their lifetime, making it the third most common type of cancer in the country. The average...

Prostatepedia December 2019

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment - ScienceDirect : Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer …

Why Are So Many People Misinterpreting the ACS Prostate Cancer Data? | Prostate Cancer Foundation : Since the American Cancer Society (ACS) released their annual Cancer Facts & Figures report for 2020, there’s been a lot of commentary on the internet about prostate cancer death rates. Some of the loudest voices are howling that the prostate cancer problem is getting worse. The Prostate Cancer Foundation would like to take a moment …

“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now | Prostate Cancer and Prostatic Diseases

Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system | SpringerLink : The delivery of precision medicine is a primary objective for both clinical and translational investigators. Patients with newly diagnosed prostate cancer

“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now | Prostate Cancer and Prostatic Diseases

Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. - PubMed - NCBI : PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

An Intimacy Intervention for Couples Completing Breast or Prostate Cancer - Full Text View - ClinicalTrials.gov : An Intimacy Intervention for Couples Completing Breast or Prostate Cancer - Full Text View.

Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable - International Journal of Radiation Oncology • Biology • Physics : Advances in positron emission tomography (PET) imaging with prostate-specific tracers allow more sensitive and specific detection of low-volume recurrences that were previously indiscernible using conventional imaging. Retrospective data in patients presenting with N1M0 prostate cancer support combined-modality therapy with radiation and androgen deprivation therapy, and preliminary data from the Radiation Therapy Oncology Group 0534 randomized trial suggest that salvage pelvic nodal radiation therapy with androgen deprivation therapy is safe and effective for patients with biochemical recurrence after prostatectomy.

Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable? - ScienceDirect

Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable - ScienceDirect

Novel Imaging Slated to Change Trajectory of Prostate Cancer Treatment : Hussein Aoun, MD, discusses the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer. onclive.com Novel Imaging Slated to Change Trajectory of Prostate Cancer Treatment 3-4 minutes Hussein Aoun, MD Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD. “With MRI, we can identify clinically significant lesions and stage local disease to see if there is extraprostatic extension. In terms of metastatic or early recurrent disease, we have PET scans with agents such as 18F-fluciclovine (Axumin), where we can identify lesions earlier that we would not have seen previously with a CT scan or conventional bone s

Adult Urology | Journal of Urology auajournals.org Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center Karim Touijer 2-3 minutes Abstract Purpose: To study the risk of metastatic prostate cancer development in men with Grade Group 2 disease being managed with active surveillance (AS) at Memorial Sloan Kettering Cancer Center. Materials and Methods: 219 men with Grade Group 2 prostate cancer were managed with AS between 2000–2017. Biopsy was performed every 2–3 years or upon changes in magnetic resonance imaging, prostate-specific antigen (PSA) level, or digital rectal examination. The primary outcome was development of distant metastasis. The Kaplan-Meier method was used to estimate treatment-free survival. Results: The median age at diagnosis

Saccharin derivatives give cancer cells a not-so-sweet surprise - American Chemical Society : American Chemical Society: Chemistry for Life.

Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy

Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management

Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy

A physician's inaccurate cancer prognosis : I did not try to excuse the physician’s inaccurate prognosis, and I repeated to Mr. G that we have medications that can prolong his life.

The Horse is at the Stable Door: Management of N1M0 Prostate Cancer - Clinical Oncology : Pelvic lymph node involvement in prostate cancer is a significant poor prognostic factor with very little evidence on the optimal management options for these patients. It is estimated that lymph node-positive patients make up 12% of newly diagnosed prostate cancer and this figure is expected to rise with the advancement and increasing use of novel imaging. The controversy around this subgroup of patients is whether this is an intermediary stage before disseminated disease and hence amenable to curative treatment options.

Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression - Clinical Genitourinary Cancer : Micro-AbstractThis article focuses on prostate cancer (PCa) progression. The study population consisted of patients recruited from urologic clinics at the University of Cincinnati Medical Center. Our study suggests that lipid oxidation is an important mechanism for PCa progression and may serve as a biological predictor of PCa progression.

How Lack of Access to Prostate Care Determines Outcomes of Underserved Populations | UCSF Radiology : When it comes to medical care, many factors can determine the types of treatment and medications that are available to patients. Often times, populations with less access to adequate care, particularly with regards to specialized treatment for diseases like prostate cancer, may experience poorer outcomes.

Qualitative and quantitative reproducibility of [18]fluoromethycholine PET/computed tomography in prostate cancer : BackgroundRecurrence occurs in more than 50% of prostate cancer. To be effective, treatments require precise localization of tumor cells. [18F]fluoromethylcholine ([18F]FCH) PET/computed tomography (CT) is currently used to restage disease in cases of biochemical relapse. To be used for therapy resp

Prostate Cancer in Black Men: Overcoming Barriers to Better Outcomes : Black men are more than twice as likely as white men to die of prostate cancer. Learn about the many reasons and what you can do about it.

Antiandrogens Augment Growing Armamentarium in Metastatic Prostate Cancer : Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.

Saccharin Derivatives May Kill Cancer Cells | Cooking with Kathy Man : Saccharin received a bad rap after studies in the 1970s linked consumption of large amounts of the artificial sweetener to bladder cancer in laboratory rats. Later, research revealed that these fin…